Hot or Not, Stock Market Edition: 05/21/2026

Happy Thursday. Here’s what’s trending (in both directions) according to our Zen Ratings quant rating system:

• Hot: Brazilian telecom player TIM SA (TIMB) is looking good after a big dip; enterprise data giant Teradata (TDC) is in full comeback mode
• Not: Biotech developer Erasca (ERAS) faces big setbacks; Carlyle Group (CG) isn’t pleasing investors RN 

P.S. Get Pre-IPO Exposure to ChatGPT (Ticker Revealed)... Act BEFORE IPO Announcement as Early as June 11! Click Here for Details! 

A note from our sponsors...

🔥 HOT: Brazilian telecom player TIM SA (TIMB) is starting to look attractive again after a recent pullback (the stock is down about 15% in the past month). Credit goes to improving profitability from Brazil’s 5G expansion cycle. TIM has already invested heavily in network upgrades, and now the focus is shifting toward monetizing that infrastructure through higher-value subscribers, better margins, and expanding digital services. That’s why some analysts believe the recent weakness was overdone — the underlying business trends remain solid even as the stock cooled off from prior highs. At the same time, the shares now trade meaningfully below their peak, creating a potential buy-the-dip setup in one of the stronger telecom operators in Latin America. In the Zen Ratings, TIMB holds a high-tier B (Buy) rating and ranks near the top of the telecom industry, supported by strong Component Grades across Financials, Growth, Momentum, Safety, and Value. All said? This looks like a classic case of a quality operator pulling back within a longer-term uptrend — and if execution stays on track, the recent weakness may end up looking like an opportunity rather than a warning sign.

🥶 NOT: Cancer biotech developer Erasca (ERAS) is running into a serious setback following a patient death tied to an early-stage clinical trial, which immediately raised concerns about both safety and the long-term viability of the company’s lead programs. In biotech, confidence is everything — and once safety questions enter the picture, investors tend to pull back fast. That concern has only intensified as multiple law firms launched investigations tied to potential securities claims, adding another layer of uncertainty around the story. The stock’s sharp collapse from its highs reflects a market that’s no longer pricing ERAS as a promising growth biotech, but as a company now fighting to rebuild credibility. According to WallStreetZen, ERAS carries a near-bottom-tier D (Sell) rating, dragged down by extremely weak Sentiment along with poor Financials, Safety, and AI scores. The bottom line? If you’re holding, consider selling. (Here’s more on when it’s time to sell a stock.) Early-stage biotech investing is already risky — but this is next-level. 

🔥 HOT: Enterprise data giant Teradata (TDC) is quietly staging a comeback that’s already picking up steam with 20% gains in the past month. What’s driving the move? The enterprise AI arms race, natch. As corporations rush to modernize their data infrastructure for AI, Teradata is benefiting from something incredibly valuable: large enterprises already trust its platform with mission-critical data. Investors are beginning to notice the shift, with the stock rebounding strongly from its lows as confidence builds around the company’s ability to monetize the AI transition. According to WallStreetZen, TDC now holds a top-tier Zen Rating (A / Strong Buy), powered by standout Component Grades for Financials and strong support from Safety and Value. In a nutshell? Teradata may not be the flashiest AI stock, but it’s a solid “picks-and-shovels” enterprise AI play, and those often end up being some of the most durable winners. (Looking for more hidden AI winners? Watch our latest video on the topic here.)

🥶 NOT: Asset manager Carlyle Group (CG) is running into the same problem hitting much of the alternative asset world right now: great long-term businesses trapped in a difficult short-term cycle. We’re in the midst of an industry-wide slowdown in deal exits and fundraising momentum, which directly pressures fee growth and profitability for firms like Carlyle. That weakness showed up clearly in the latest quarter, where the company reported disappointing earnings, falling revenue, and a net loss that rattled investors. At the same time, stress is starting to build across parts of the private credit and leveraged buyout landscape as higher interest rates make financing and exits more challenging. Analysts have responded by trimming targets and lowering expectations, signaling that the market may be preparing for a longer slowdown in private markets activity. According to WallStreetZen, CG now carries a D (Sell) rating, dragged down by weak Growth and Sentiment scores. True, Carlyle still has a respected franchise — but right now, the macro backdrop for private equity is working against it, and it could struggle for the foreseeable future.

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.